273 related articles for article (PubMed ID: 11351351)
1. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.
Lin DL; Tarnowski CP; Zhang J; Dai J; Rohn E; Patel AH; Morris MD; Keller ET
Prostate; 2001 May; 47(3):212-21. PubMed ID: 11351351
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
Dorai T; Dutcher JP; Dempster DW; Wiernik PH
Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC
Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764
[TBL] [Abstract][Full Text] [Related]
8. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
[TBL] [Abstract][Full Text] [Related]
9. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
10. Bone morphogenetic protein signaling in prostate cancer cell lines.
Brubaker KD; Corey E; Brown LG; Vessella RL
J Cell Biochem; 2004 Jan; 91(1):151-60. PubMed ID: 14689587
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
12. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
[TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Holen I; Croucher PI; Hamdy FC; Eaton CL
Cancer Res; 2002 Mar; 62(6):1619-23. PubMed ID: 11912131
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts.
Rifas L; Arackal S; Weitzmann MN
J Cell Biochem; 2003 Mar; 88(4):650-9. PubMed ID: 12577299
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.
Masuda H; Fukabori Y; Nakano K; Takezawa Y; CSuzuki T; Yamanaka H
Prostate; 2003 Mar; 54(4):268-74. PubMed ID: 12539225
[TBL] [Abstract][Full Text] [Related]
17. MG-63 osteoblast-like cells enhance the osteoprotegerin expression of PC-3 prostate cancer cells.
Katopodis H; Philippou A; Tenta R; Doillon C; Papachroni KK; Papavassiliou AG; Koutsilieris M
Anticancer Res; 2009 Oct; 29(10):4013-8. PubMed ID: 19846944
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.
Corey E; Quinn JE; Bladou F; Brown LG; Roudier MP; Brown JM; Buhler KR; Vessella RL
Prostate; 2002 Jun; 52(1):20-33. PubMed ID: 11992617
[TBL] [Abstract][Full Text] [Related]
19. Effect of carnosine on runt-related transcription factor-2/core binding factor alpha-1 and Sox9 expressions of human periodontal ligament cells.
Ito-Kato E; Suzuki N; Maeno M; Takada T; Tanabe N; Takayama T; Ito K; Otsuka K
J Periodontal Res; 2004 Jun; 39(3):199-204. PubMed ID: 15102049
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function.
Brubaker KD; Vessella RL; Brown LG; Corey E
Prostate; 2003 Jun; 56(1):13-22. PubMed ID: 12746842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]